UPDATE: Brean Capital Lowers PT on Nektar Therapeutics Following NKTR-181 Phase 2 Trial Miss

In a report published Friday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Nektar Therapeutics (NASDAQ: NKTR ), but lowered the price target from $17.00 to $14.00. In the report, Brean Capital noted, “Nektar missed the primary endpoint in its Phase 2 trial with NKTR-181 in chronic pain